Study of Drug Resistance in Enterobacter aerogenes
Author Information
Author(s): Chevalier Jacqueline, Mulfinger Céline, Garnotel Eric, Nicolas Pierre, Davin-Régli Anne, Pagès Jean-Marie
Primary Institution: UMR-MD1, IFR 48, Facultés de Médecine et de Pharmacie, Marseille, France
Hypothesis
How has the prevalence of drug efflux pumps in Enterobacter aerogenes changed between 1995 and 2003?
Conclusion
There has been a noticeable increase in clinical isolates of Enterobacter aerogenes with efflux mechanisms that are susceptible to pump inhibitors over an eight-year period.
Supporting Evidence
- Resistance to chloramphenicol increased from 61% in 1995 to 74-83% in 2003.
- 40% of non-susceptible isolates showed increased susceptibility to chloramphenicol when treated with the efflux pump inhibitor PAßN.
- An active efflux pump was identified in resistant E. aerogenes strains, indicating a mechanism for antibiotic resistance.
Takeaway
This study looked at bacteria that can resist antibiotics and found that more of them can now push out the medicine, making it harder to treat infections.
Methodology
The study involved screening clinical isolates of Enterobacter aerogenes from 1995 and 2003 for antibiotic resistance and the role of efflux pumps using drug susceptibility assays and efflux pump inhibitors.
Potential Biases
Potential bias due to the selection criteria for isolates and the specific hospital settings.
Limitations
The study is limited to isolates from a specific geographic area and may not represent global trends.
Participant Demographics
Clinical isolates from hospitals in Marseille, France.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website